Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial

Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial

Background: Prevention of the development of micro-and macrovascular complications in patients with diabetes melli-tus (DM) encouraged the search for insulin analogues that allow imitating, as close as possible, a normal physiological insulin secretion in healthy people. Biosimilars (bioanalogues of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Alexander Y. Mayorov, Roman V. Drai, Tatiana L. Karonova, Olga I. Avdeeva, Igor E. Makarenko, Ekaterina O. Koksharova, Ekaterina Е. Mishina, Yulia А. Sevastyanova, Olena V. Afonkina
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2020
Materias:
insulin glargin
biosimilar
pharmacokinetics
pharmacodynamics
comparability
glucose infusion rate
ringlar
lantus
Nutritional diseases. Deficiency diseases
RC620-627
Acceso en línea:https://doaj.org/article/b3a6691ae08b4a68a1b2aa25127806f7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares